Clinical trial · Observational
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Coronavirus | — | UNRESOLVED | — |
| Monoclonal Gammopathy of Undetermined Significance | Monoclonal Gammopathy of Undetermined Significance | ONTOLOGY_EXACT | 0.98 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MGUS, SMM, MM Patients or their Caregivers
- description
- Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile. The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility. Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete.
- interventionNames
- Behavioral: Questionnaire
Primary outcomes (4)
- measure
- COVID-19 Diagnosis and Treatment
- timeFrame
- Up to one year
- description
- Describe how patients diagnosed with COVID-19 were treated for the virus.
- measure
- Changes to Myeloma Treatment and Care
- timeFrame
- Up to one year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma. * Access to a computer or electronic device with internet access, or phone * Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma * Willing to give electronically-signed consent * Ability to read questions in English
References
Publications (0)
Data not yet available